Blueprint Medicines Corporation

NasdaqGS:BPMC Voorraadrapport

Marktkapitalisatie: US$6.0b

Blueprint Medicines Beheer

Beheer criteriumcontroles 3/4

De CEO Blueprint Medicines is Kate Haviland, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.43M, bestaande uit 12.2% salaris en 87.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.094% van de aandelen van het bedrijf, ter waarde $ 5.62M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 9.5 jaar.

Belangrijke informatie

Kate Haviland

Algemeen directeur

US$6.4m

Totale compensatie

Percentage CEO-salaris12.2%
Dienstverband CEO2.6yrs
Eigendom CEO0.09%
Management gemiddelde ambtstermijn4.2yrs
Gemiddelde ambtstermijn bestuur9.5yrs

Recente managementupdates

Recent updates

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Nov 24
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Sep 27

Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Aug 16
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Jul 23
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Blueprint Medicines: Overdue For A Breather

Jul 16

Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 05
Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Blueprint Medicines: Rampant Growth Mostly Priced In

May 04

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Apr 05
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 08
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Dec 18
Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Nov 20
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Jul 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Apr 16
Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Nov 07
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Sep 15

Blueprint to seek label expansion for systemic mastocytosis therapy after trial win

Aug 17

Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance

Aug 02

Analyse CEO-vergoeding

Hoe is Kate Haviland's beloning veranderd ten opzichte van Blueprint Medicines's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$128m

Jun 30 2024n/an/a

-US$205m

Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$6mUS$782k

-US$507m

Sep 30 2023n/an/a

-US$555m

Jun 30 2023n/an/a

-US$554m

Mar 31 2023n/an/a

-US$581m

Dec 31 2022US$6mUS$701k

-US$558m

Sep 30 2022n/an/a

-US$718m

Jun 30 2022n/an/a

-US$702m

Mar 31 2022n/an/a

-US$650m

Dec 31 2021US$4mUS$501k

-US$644m

Sep 30 2021n/an/a

-US$411m

Jun 30 2021n/an/a

US$340m

Mar 31 2021n/an/a

US$325m

Dec 31 2020US$2mUS$461k

US$314m

Sep 30 2020n/an/a

US$333m

Jun 30 2020n/an/a

-US$395m

Mar 31 2020n/an/a

-US$371m

Dec 31 2019US$3mUS$432k

-US$348m

Sep 30 2019n/an/a

-US$362m

Jun 30 2019n/an/a

-US$340m

Mar 31 2019n/an/a

-US$267m

Dec 31 2018US$3mUS$393k

-US$237m

Sep 30 2018n/an/a

-US$205m

Jun 30 2018n/an/a

-US$170m

Mar 31 2018n/an/a

-US$177m

Dec 31 2017US$1mUS$353k

-US$148m

Compensatie versus markt: De totale vergoeding ($USD 6.43M ) Kate } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.78M ).

Compensatie versus inkomsten: De vergoeding van Kate is gestegen terwijl het bedrijf verliesgevend is.

CEO

Kate Haviland (48 yo)

2.6yrs

Tenure

US$6,432,012

Compensatie

Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Kathryn Haviland
President2.6yrsUS$6.43m0.094%
$ 5.6m
Alexis Borisy
Co-Founder & Directorno dataUS$397.33k0.11%
$ 6.8m
Michael Landsittel
Chief Financial Officer8.8yrsUS$2.19m0.056%
$ 3.4m
Christina Rossi
Chief Operating Officer2.6yrsUS$2.81m0.043%
$ 2.6m
Percy Carter
Chief Scientific Officer3.5yrsUS$2.30m0.078%
$ 4.6m
Fouad Namouni
President of Research & Development4.2yrsUS$2.80m0.050%
$ 3.0m
Ariel Hurley
Senior VP1.8yrsgeen gegevens0.023%
$ 1.4m
Jenna Cohen
Senior Director & Head of Investor Relationsno datageen gegevensgeen gegevens
Tracey McCain
Executive VP8.2yrsUS$2.34m0.046%
$ 2.7m
Debra Durso-Bumpus
Chief People Officer4.8yrsgeen gegevens0.019%
$ 1.2m
Julian Baker
Senior Vice President of Corporate Affairsno datageen gegevensgeen gegevens
Becker Hewes
Chief Medical Officer4.5yrsgeen gegevens0.046%
$ 2.8m

4.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BPMC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Kathryn Haviland
President2.6yrsUS$6.43m0.094%
$ 5.6m
Alexis Borisy
Co-Founder & Director13.6yrsUS$397.33k0.11%
$ 6.8m
George Demetri
Chair of Scientific Advisory Board12.5yrsUS$333.38kgeen gegevens
Lynn Seely
Lead Independent Director8.6yrsUS$452.33k0.017%
$ 1.0m
Charles Sawyers
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Brian Druker
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Nicholas Lydon
Member of Scientific Advisory Board & Independent Director13.6yrsUS$417.33k0.088%
$ 5.2m
Lonnel Coats
Independent Director8.8yrsUS$419.33k0%
$ 0
William Hahn
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Scott Lowe
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Daniella Beckman
Independent Director2.9yrsUS$422.33k0.014%
$ 807.4k
Jeffrey Albers
Chairman10.3yrsUS$526.08k0.24%
$ 14.6m

9.5yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BPMC wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).